UNSPSC 51282121: Sulbactam

This classification denotes a beta-lactam antibiotic with the molecular formula C8H11NO5S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier S4TF6I2330, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2s-cis)- but more generally known as sulbactam, which bears U.S. National Institutes of Health Compound Identifier 50161. The European Medicines Agency schedules Sulbactam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10676MIG.

UNSPSC 51282121 Sulbactam (Commodity) does not align with the recent state and local solicitations tagged under this code. The recent opportunities in the block—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, general medical and first aid supplies, and generic pharmaceuticals—are health and medical product procurements that fall outside the scope of sulbactam, a beta-lactamase inhibitor antibiotic. The mismatch suggests either a tagging error in the underlying procurement systems or that state and local buyers are using this code to capture a broader family of pharmaceutical purchases that does not correspond to sulbactam specifically. State and local purchasing offices are acquiring pharmaceutical products through multiple channels: direct purchase via competitive bid (City of Tampa), cooperative purchasing vehicles (MMCAP serving multiple states), and exploratory RFIs to understand vendor capability in direct-to-manufacturer contracting (Texas HHS Commission). Issuing bodies include city departments (Tampa), county health agencies (Seminole County, Florida), state health commissions (Texas HHS), and multi-state cooperative purchasing alliances (MMCAP, which encompasses Minnesota and Oregon membership).

The geographic spread spans Florida, Texas, Minnesota, and Oregon based on recent postings. Representative recent opportunities include the City of Tampa's IFB for medical and first aid supplies (169 line items, $700 thousand estimated contract value, with a 5 percent SLBE bid discount), Seminole County's IFB for naloxone and drug deactivation systems (1,900 units annually, quarterly delivery, due July 26, 2023), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, serving state and local facilities across participating states). The Texas HHS RFI posted April 3, 2026 signals emerging procurement interest in direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. Given the code-to-opportunity mismatch, pursuit under sulbactam specifically is unlikely to be productive; business development effort would benefit from clarification of whether your firm's pharmaceutical offerings align with the actual commodity families these buyers are tagging in their procurement systems.